Skip to Main content Skip to Navigation
Journal articles

External quality assessment of Rift Valley fever diagnosis in countries at risk of the disease: African, Indian Ocean and Middle-East regions

Aurélie Pedarrieu 1, 2 Fatiha El Mellouli 3 Hanane Khallouki 3 Khalil Zro 4 Ghizlane Sebbar 4 Soufien Sghaier 5 Hafsa Madani 6 Nadera Bouayed 6 Modou Moustapha Lo 7 Mariame Diop 7 Ahmed Bezeid Ould El Mamy 8 Yahya Barry 8 Marthin Dakouo 9 Abdallah Traore 9 Haladou Gagara 10 Maman Moutari Souley 10 Sara Acha 11 Laurenco Mapaco 11 Jelly Chang'A 12 Denis Nyakilinga 12 Baratang Lubisi 13 Thabisile Tshabalala 13 Claudia Filippone 14 Jean-Michel Heraud 14 Sitty-Bahyat Chamassy 15 Abdou Achiraffi 15 Nicolas Keck 16 Gilda Grard 17, 18 Kareem Abdelfattah Abdelwahab Mohammed 19 Abdulwahed Mohammed Alrizqi 19 Catherine Cetre-Sossah 1, 2, *
Abstract : Rift Valley fever virus (RVFV), an arbovirus belonging to the Phlebovirus genus of the Phenuiviridae family, causes the zoonotic and mosquito-borne RVF. The virus, which primarily affects livestock (ruminants and camels) and humans, is at the origin of recent major outbreaks across the African continent (Mauritania, Libya, Sudan), and in the South-Western Indian Ocean (SWIO) islands (Mayotte). In order to be better prepared for upcoming outbreaks, to predict its introduction in RVFV unscathed countries, and to run efficient surveillance programmes, the priority is harmonising and improving the diagnostic capacity of endemic countries and/or countries considered to be at risk of RVF. A serological inter-laboratory proficiency test (PT) was implemented to assess the capacity of veterinary laboratories to detect antibodies against RVFV. A total of 18 laboratories in 13 countries in the Middle East, North Africa, South Africa, and the Indian Ocean participated in the initiative. Two commercial kits and two in-house serological assays for the detection of RVFV specific IgG antibodies were tested. Sixteen of the 18 participating laboratories (88.9%) used commercial kits, the analytical performance of test sensitivity and specificity based on the seroneutralisation test considered as the reference was 100%. The results obtained by the laboratories which used the in-house assay were correct in only one of the two criteria (either sensitivity or specificity). In conclusion, most of the laboratories performed well in detecting RVFV specific IgG antibodies and can therefore be considered to be prepared. Three laboratories in three countries need to improve their detection capacities. Our study demonstrates the importance of conducting regular proficiency tests to evaluate the level of preparedness of countries and of building a network of competent laboratories in terms of laboratory diagnosis to better face future emerging diseases in emergency conditions.
Complete list of metadata

https://hal-pasteur.archives-ouvertes.fr/pasteur-03250460
Contributor : Jean-Michel Heraud <>
Submitted on : Friday, June 4, 2021 - 4:50:59 PM
Last modification on : Friday, June 18, 2021 - 10:02:01 AM

File

journal.pone.0251263.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Citation

Aurélie Pedarrieu, Fatiha El Mellouli, Hanane Khallouki, Khalil Zro, Ghizlane Sebbar, et al.. External quality assessment of Rift Valley fever diagnosis in countries at risk of the disease: African, Indian Ocean and Middle-East regions. PLoS ONE, Public Library of Science, 2021, 16 (5), pp.e0251263. ⟨10.1371/journal.pone.0251263⟩. ⟨pasteur-03250460⟩

Share

Metrics

Record views

49

Files downloads

64